Biological response modifiers (immunotherapy) in combination to chemotherapy are superior to that of chemotherapy in treatment of breast cancer (triple-negative/HER-2 ( +)), multiple myeloma, and non-small-cell lung cancer. This review article consists of a total of eighteen independent randomized controlled clinical trials ranging from phases one to three. Patients were randomly selected for immunomodulatory treatment or chemotherapy and assessed for a specific mutation expression that the immunomodulatory agent targets. Kaplan–Meier plots, swimmer plots, and bar graphs depict overall/progression-free survival, objective response, and clinical response rates. The data collected was assessed by using 95% confidence interval and a p value of 0.05. Patients were treated until disease progression. Biological response modifiers (immunotherapy) resulted in significantly longer median progression-free survival in PD-L1-positive breast cancer (7.5 months compared to 5.0 months in control group), multiple myeloma (60.7% compared to 26.9% in the daratumumab and placebo groups, respectively), and in non-small-cell lung cancer (median progression-free survival was 10.3 months in the pembrolizumab group compared to 6.0 months in the chemotherapy group): higher complete responses in multiple myeloma (79% and 66% in the elotuzumab and control groups, respectively) and lower disease progression in PD-L1-positive non-small-cell lung cancer (62.1% of pembrolizumab versus 50.3% of chemotherapy patients had no disease progression at 6 months). Combination biological response modifiers (immunotherapy) and chemotherapy displayed benefit in overall/progression-free survival, response rate, duration of response, clinical benefit, and invasive disease-free survival in triple-negative/HER2-2( +) breast cancer, multiple myeloma, and non-small-cell lung cancer.

中文翻译：

---

三阴性/Her2(+) 乳腺癌、多发性骨髓瘤和非小细胞肺癌联合化疗药物和生物反应调节剂（免疫疗法）

生物反应调节剂（免疫疗法）联合化疗在治疗乳腺癌（三阴性/HER-2 (+)）、多发性骨髓瘤和非小细胞肺癌方面优于化疗。这篇综述文章共包含 18 项独立的随机对照临床试验，范围从第一阶段到第三阶段。随机选择患者进行免疫调节治疗或化疗，并评估免疫调节剂靶向的特定突变表达。Kaplan-Meier 图、游泳者图和条形图描绘了总体/无进展生存期、客观反应和临床反应率。使用 95% 置信区间和 0.05 的 p 值评估收集的数据。患者接受治疗直至疾病进展。